America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the unique mechanisms by which AOH1996 targets cancer cells compared to traditional chemotherapy treatments?
**Interview with Dr. Linda Malkas on Targeted Cancer Drug AOH1996**
**Editor:** Good afternoon, Dr. Malkas. Thank you for joining us today to discuss your groundbreaking work on the targeted cancer drug AOH1996. To begin with, could you explain to our audience what AOH1996 is and how it functions?
**Dr. Malkas:** Good afternoon! AOH1996 is an innovative targeted chemotherapy drug developed here at City of Hope. It works by targeting a specific variant of the PCNA protein, which is crucial for DNA replication and tumor growth. Think of PCNA as a large airport hub; in cancer cells, this hub is uniquely mutated. AOH1996 acts like a blizzard that disrupts this hub, effectively shutting down the operations that allow cancer cells to proliferate.
**Editor:** That’s a fascinating analogy. Can you tell us about the development process of AOH1996? How long has it been in the works?
**Dr. Malkas:** The development of AOH1996 has spanned nearly two decades. During this time, we conducted extensive research, which included testing the drug on over 70 different cancer cell lines. Our studies have shown that AOH1996 can selectively kill cancer cells by disrupting their normal reproductive processes, which is critical for their survival.
**Editor:** It’s impressive to hear about such rigorous testing. What types of cancer has AOH1996 been found to be effective against?
**Dr. Malkas:** AOH1996 shows promise in treating several types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. The versatility of this drug is one of its significant advantages, offering hope for a wide range of patients.
**Editor:** What are the next steps for AOH1996 in terms of clinical development?
**Dr. Malkas:** The next step is to advance our findings into clinical trials with human patients. These trials will be essential to confirm the drug’s effectiveness and safety in a clinical setting. We are eager to see how it performs in real-world scenarios.
**Editor:** From your perspective, how do targeted therapies like AOH1996 change the landscape of cancer treatment?
**Dr. Malkas:** Targeted therapies represent a significant shift in treating cancer. Traditional chemotherapy often affects both healthy and cancerous cells, leading to severe side effects. In contrast, targeted drugs like AOH1996 are designed to specifically attack cancer cells while minimizing damage to healthy tissue. This precision allows for more effective treatments with potentially fewer side effects, improving the overall quality of life for patients.
**Editor:** Thank you, Dr. Malkas. Your work not only sounds promising but also underscores the importance of continued research in cancer therapeutics. We look forward to hearing more about your progress with AOH1996.
**Dr. Malkas:** Thank you for having me! It’s a pleasure to share our research, and I hope it brings hope to many patients battling cancer.
**Editor:** Thank you again, Dr. Malkas.
